4
Changes in Ownership
Aquestive Therapeutics, Inc. Filed Acc 0001214659-26-014337
Chief Development Officer sold 7,197 shares at $3.55 ($25,526)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Davis Matthew W. · Chief Development Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-11-12 | Sale : show line 1 in the form 10b5-1 | −7,197 | $3.55 | $25,526 | 87,500 | D |
| Open-market sales · 7,197 sh · avg $3.55 · $25,526 | ||||||
Loading xslF345X06/marketforms-74306.xml…